13F Pro13F Pro

StemPoint Capital LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1952142
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.7%$576.1M
  • Other0.3%$1.8M

AUM History

13fpro.ai/research/fund/stempoint-capital-lp-1952142

Conviction and streaks

Diversifying · top 10 = 41.2%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

ABVX$ABVXConviction hold6.5% weight · held 5 quartersRVMD$RVMDConviction hold5.2% weight · held 4 quartersDNTH$DNTHConviction hold3.4% weight · held 4 quartersMLYS$MLYSConviction hold2.8% weight · held 5 quartersSRZN$SRZNConviction hold2.4% weight · held 9 quartersDNTH$DNTHAccumulating+385% shares · 3 quarters runningMLYS$MLYSAccumulating+281% shares · 3 quarters runningIVA$IVAAccumulating+4527% shares · 2 quarters runningQURE$QUREAccumulating+103% shares · 2 quarters runningROIV$ROIVTrimming-92% shares · 3 quarters runningCYTK$CYTKTrimming-50% shares · 3 quarters runningABVX$ABVXTrimming-28% shares · 2 quarters runningCLDX$CLDXTrimming-38% shares · 2 quarters runningXENE$XENETrimming-78% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/stempoint-capital-lp-1952142

StemPoint Capital LP 13F holdings — Q2 2026

$580.5M portfolio (+8.4% QoQ) · 84 holdings · Q2 2026 13F · top 10 are 41% of the stock portfolio

Includes $2.6M of put/call options ($748K puts, $1.9M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $577.9M. Weights use the stock portfolio.

All holdings — StemPoint Capital LP (Q2 2026)

84 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
KNSA$KNSAKiniksa Pharmaceuticals International, plc$13.4MNew
SRRK$SRRKScholar Rock Holding Corp$13.2M-77%
ALKS$ALKSAlkermes plc.$13.0M+208%
TRAX$TRAXFirst Tracks Biotherapeutics, Inc.$12.5MNew
PRAX$PRAXPraxis Precision Medicines, Inc.$12.5M-34%
ROIV$ROIVRoivant Sciences Ltd.$12.3M-10%
BIOA$BIOABioAge Labs, Inc.$11.4M+37%
CGON$CGONCG Oncology, Inc.$11.3M-23%
ORKA$ORKAOruka Therapeutics, Inc.$11.1MNew
IMVT$IMVTImmunovant, Inc.$10.7M-63%
CELC$CELCCelcuity Inc.$10.3M+64%
RLMD$RLMDRELMADA THERAPEUTICS, INC.$10.1M+144%
CLYM$CLYMClimb Bio, Inc.$9.7MNew
SYRE$SYRESpyre Therapeutics, Inc.$9.5M-36%
ZURA$ZURAZura Bio Ltd$8.1M+82%

What changed in Q2 2026

Against the previous quarter's 13F: 34 new, 19 added to, 30 trimmed, 32 sold out. Share-count changes; largest moves by dollar size first.

New positions (34)

  • KNSA$KNSAKiniksa Pharmaceuticals International, plc$13.4M

    first bought this quarter

  • TRAX$TRAXFirst Tracks Biotherapeutics, Inc.$12.5M

    first bought this quarter

  • ORKA$ORKAOruka Therapeutics, Inc.$11.1M

    first bought this quarter

  • CLYM$CLYMClimb Bio, Inc.$9.7M

    first bought this quarter

  • IFRX$IFRXInflaRx N.V.$7.2M

    first bought this quarter

  • OVID$OVIDOvid Therapeutics Inc.$6.5M

    first bought this quarter

+28 more in the Excel export

Added to (19)

  • TNGX$TNGXTango Therapeutics, Inc.+509%

    now $38.2M · held 2 qtrs, 2 adds in a row

  • ERAS$ERASErasca, Inc.+553%

    now $28.7M · held 2 qtrs, 2 adds in a row

  • TYRA$TYRATyra Biosciences, Inc.+228%

    now $20.2M · held 2 qtrs, 2 adds in a row

  • DNTH$DNTHDianthus Therapeutics, Inc. /DE/+135%

    now $19.6M · held 4 qtrs, 4 adds in a row

  • SRZN$SRZNSurrozen, Inc./DE+208%

    now $13.8M · held 8+ qtrs

  • ALKS$ALKSAlkermes plc.+208%

    now $13.0M · held 2 qtrs, 2 adds in a row

+13 more in the Excel export

Trimmed (30)

  • SRRK$SRRKScholar Rock Holding Corp-77%

    now $13.2M · held 7 qtrs

  • RVMD$RVMDRevolution Medicines, Inc.-43%

    now $30.0M · held 4 qtrs

  • IMVT$IMVTImmunovant, Inc.-63%

    now $10.7M · held 8+ qtrs

  • DFTX$DFTXDefinium Therapeutics, Inc.-58%

    now $6.5M · held 2 qtrs

  • GPCR$GPCRStructure Therapeutics Inc.-81%

    now $2.0M · held 4 qtrs, 2 trims in a row

  • ARQT$ARQTArcutis Biotherapeutics, Inc.-76%

    now $2.6M · held 8+ qtrs

+24 more in the Excel export

Sold out (32)

  • SNDX$SNDXSyndax Pharmaceuticals Incwas $28.4M

    held 9+ qtrs

  • MBX$MBXMBX Biosciences, Inc.was $14.9M

    held 5 qtrs

  • BSX$BSXCALLBOSTON SCIENTIFIC CORPwas $12.5M
  • DYN$DYNDyne Therapeutics, Inc.was $9.2M

    held 3 qtrs

  • EWTX$EWTXEdgewise Therapeutics, Inc.was $9.2M

    held 2 qtrs

  • DNLI$DNLIDenali Therapeutics Inc.was $8.2M

    held 8+ qtrs

+26 more in the Excel export

Firm AUM (Form ADV): $761.3M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F StemPoint Capital LP has filed, 10 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow StemPoint Capital?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.

Average quality of StemPoint Capital's top 20 holdings: 26/100 (our AI quality score, weighted by position size; 4 of the 20 are scored)

Top 10 since filing

-14.4%

Value-weighted move of the 10 largest stock positions

Turnover

46%

Last quarter; 192% over the last 4

Top 10 weight

41%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

34%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

StemPoint Capital LP disclosed 84 positions worth $580.5M in its Form 13F-HR for Q2 2026 — $577.9M in common stock plus $2.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $TNGX (Tango Therapeutics, Inc.) at 6.6% of the equity portfolio, followed by $ABVX and $RVMD. During the quarter the fund opened 34 new positions and exited 32 — including a new stake in $KNSA and a full exit from $SNDX. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from StemPoint Capital LP’s Form 13F-HR filing with the SEC under CIK 1952142.

Funds like this

managers whose biggest positions overlap StemPoint Capital's
TCG Crossover Management, LLC$4.16B 13F book · 15 shared top holdingsTNGXABVXDNTHTYRALogos Global Management LP$2.32B 13F book · 12 shared top holdingsABVXRVMDERASTNGXAffinity Asset Advisors, LLC$2.21B 13F book · 16 shared top holdingsERASALKSRVMDPRAXCormorant Asset Management, LP$1.95B 13F book · 15 shared top holdingsERASABVXDNTHPRAXSiren, L.L.C.$4.94B 13F book · 10 shared top holdingsERASTNGXRVMDSRRKFirst Turn Management, LLC$934.72M 13F book · 12 shared top holdingsABVXRVMDDNTHELVN

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: StemPoint Capital LP

13F Pro is an AI hedge fund tracker and stock research platform. For StemPoint Capital LP (SEC CIK: 1952142), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in StemPoint Capital LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.